348 related articles for article (PubMed ID: 34107772)
1. Photoablative atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis in instent femoro-popliteal obstructions (PHOTOPAC).
Böhme T; Noory E; Beschorner U; Lerke F; Schmidt A; Scheinert D; Ito W; Zeller T; Rastan A
Vasa; 2021 Sep; 50(5):387-393. PubMed ID: 34107772
[No Abstract] [Full Text] [Related]
2. Turbo-Power™ Laser Atherectomy Combined with Drug-coated Balloon Angioplasty is Associated with Improved One-Year Outcomes for the Treatment of Tosaka II and III Femoropopliteal In-stent Restenosis.
Giannopoulos S; Kokkinidis DG; Jawaid O; Behan S; Hossain P; Alvandi B; Foley TR; Singh GD; Waldo SW; Armstrong EJ
Cardiovasc Revasc Med; 2020 Jun; 21(6):771-778. PubMed ID: 31761634
[TBL] [Abstract][Full Text] [Related]
3. Matched comparison of uncoated and paclitaxel-coated balloon angioplasty for isolated popliteal lesions excluding bail-out stenting.
Böhme T; Noory E; Beschorner U; Bollenbacher R; Nührenberg T; Rastan A; Westermann D; Zeller T
Cardiovasc Revasc Med; 2024 Jun; 63():54-58. PubMed ID: 38245433
[TBL] [Abstract][Full Text] [Related]
4. Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Isolated Popliteal Artery Lesions.
Stavroulakis K; Schwindt A; Torsello G; Stachmann A; Hericks C; Bosiers MJ; Beropoulis E; Stahlhoff S; Bisdas T
J Endovasc Ther; 2017 Apr; 24(2):181-188. PubMed ID: 28008792
[TBL] [Abstract][Full Text] [Related]
5. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
[TBL] [Abstract][Full Text] [Related]
6. Laser atherectomy and drug-coated balloons for the treatment of femoropopliteal in-stent restenosis: 2-Year outcomes.
Kokkinidis DG; Behan S; Jawaid O; Hossain P; Giannopoulos S; Singh GD; Laird JR; Valle JA; Waldo SW; Armstrong EJ
Catheter Cardiovasc Interv; 2020 Feb; 95(3):439-446. PubMed ID: 31816169
[TBL] [Abstract][Full Text] [Related]
7. Network Meta-Analysis of All Available Regimens Based on Drug-Coated Balloon Angioplasty and Laser Atherectomy for Femoropopliteal In-Stent Restenosis.
Yu C; Tang W; Ren T; Chen Q; Lu R; Gao Y
J Endovasc Ther; 2024 Jun; 31(3):390-399. PubMed ID: 36189843
[TBL] [Abstract][Full Text] [Related]
8. One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
Stabile E; Gerardi D; Magliulo F; Zhelev D; Chervenkoff V; Taeymans K; Kotasov D; Goverde P; Giugliano G; Trimarco B; Esposito G
J Endovasc Ther; 2019 Feb; 26(1):26-30. PubMed ID: 30760132
[TBL] [Abstract][Full Text] [Related]
9. Drug-Coated Balloon Angioplasty Versus Standard Uncoated Balloon Angioplasty for Long Femoropopliteal Lesions: Post Hoc Analysis of the 24-Month Results of the AcoArt I Study.
Jia S; Liu J; Sun G; Zhang J; Zhuang B; Jia X; Fu W; Wu D; Wang F; Zhao Y; Guo P; Bi W; Wang S; Guo W;
Ann Vasc Surg; 2022 May; 82():70-80. PubMed ID: 34902474
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes with Jetstream atherectomy with or without drug coated balloons in treating femoropopliteal arteries: A single center experience (JET-SCE).
Shammas NW; Shammas GA; Jones-Miller S; Shammas WJ; Bou-Dargham B; Shammas AN; Banerjee S; Rachwan RJ; Daher GE
Cardiovasc Revasc Med; 2018 Oct; 19(7 Pt A):771-777. PubMed ID: 30420096
[TBL] [Abstract][Full Text] [Related]
11. Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study.
Zeller T; Langhoff R; Rocha-Singh KJ; Jaff MR; Blessing E; Amann-Vesti B; Krzanowski M; Peeters P; Scheinert D; Torsello G; Sixt S; Tepe G;
Circ Cardiovasc Interv; 2017 Sep; 10(9):e004848. PubMed ID: 28916599
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: One-year single centre clinical results.
Cioppa A; Stabile E; Popusoi G; Salemme L; Cota L; Pucciarelli A; Ambrosini V; Sorropago G; Tesorio T; Agresta A; Biamino G; Rubino P
Cardiovasc Revasc Med; 2012; 13(4):219-23. PubMed ID: 22632996
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of adjunctive drug-coated balloon therapy in endovascular treatment of common femoral artery disease.
Imran HM; Hyder ON; Soukas PA
Cardiovasc Revasc Med; 2019 Mar; 20(3):210-214. PubMed ID: 29970328
[TBL] [Abstract][Full Text] [Related]
14. Six-Month Outcomes From the First-in-Human, Single-Arm SELUTION Sustained-Limus-Release Drug-Eluting Balloon Trial in Femoropopliteal Lesions.
Zeller T; Brechtel K; Meyer DR; Noory E; Beschorner U; Albrecht T
J Endovasc Ther; 2020 Oct; 27(5):683-690. PubMed ID: 32666871
[No Abstract] [Full Text] [Related]
15. Directional atherectomy before paclitaxel coated balloon angioplasty in complex femoropopliteal disease: The VIVA REALITY study.
Rocha-Singh KJ; Sachar R; DeRubertis BG; Nolte-Ernsting CCA; Winscott JG; Krishnan P; Scott EC; Garcia LA; Baeriswyl JL; Ansel G; Rosenfield K; Zeller T;
Catheter Cardiovasc Interv; 2021 Sep; 98(3):549-558. PubMed ID: 34080792
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
Tepe G; Schroeder H; Albrecht T; Reimer P; Diehm N; Baeriswyl JL; Brechtel K; Speck U; Zeller T
J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
[No Abstract] [Full Text] [Related]
17. The effectiveness of the paclitaxel-coated Luminor® balloon catheter versus an uncoated balloon catheter in superficial femoral and popliteal arteries in preventing vessel restenosis or reocclusion: study protocol for a randomized controlled trial.
Teichgräber U; Aschenbach R; Scheinert D; Zeller T; Brechtel K; Thieme M; Blessing E; Treitl M; Lichtenberg M; von Flotow P; Vogel B; Werk M; Riambau V; Wienke A; Lehmann T; Sixt S
Trials; 2016 Oct; 17(1):528. PubMed ID: 27793175
[TBL] [Abstract][Full Text] [Related]
18. Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Common Femoral Artery Atherosclerotic Disease.
Stavroulakis K; Schwindt A; Torsello G; Beropoulis E; Stachmann A; Hericks C; Bollenberg L; Bisdas T
J Endovasc Ther; 2018 Feb; 25(1):92-99. PubMed ID: 29251204
[TBL] [Abstract][Full Text] [Related]
19. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.
Caradu C; Lakhlifi E; Colacchio EC; Midy D; Bérard X; Poirier M; Ducasse E
J Vasc Surg; 2019 Sep; 70(3):981-995.e10. PubMed ID: 31126769
[TBL] [Abstract][Full Text] [Related]
20. Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Proximal Popliteal Arteries: One-Year Results of the MDT-2113 SFA Japan Randomized Trial.
Iida O; Soga Y; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H;
J Endovasc Ther; 2018 Feb; 25(1):109-117. PubMed ID: 29264999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
